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Abstract
Background: Extracellular matrix homeostasis is strictly maintained by a coordinated balance between the
expression of metalloproteinases (MMPs) and their inhibitors. The purpose of this study was to investigate whether
the expression of MMP-9, MMP-2 and its specific inhibitors, are expressed in a reproducible, specific pattern and if
the profiles are related to prognosis in Bladder Cancer (BC).
Methods: MMP-9, MMP-2 and its specific inhibitors expression levels were analyzed by quantitative real-time
polymerase chain reaction (qRT-PCR) in fresh-frozen malignant tissue collected from 40 patients with BC submitted
to transurethral resection of bladder. The control group consisted of normal bladder tissue from five patients who
had undergone retropubic prostatectomy to treat benign prostatic hyperplasia.
Results: MMP-9 was overexpressed in 59.0 % of patients, and MMP-2, TIMP-1, TIMP-2, MMP-14, RECK and IL-8 was
underexpressed in most of the patients. Regarding prognostic parameters we observed that high-grade tumors
exhibited significantly higher levels of MMP-9 and IL-8 (p = 0.012, p = 0.003). Invasive tumors (pT1-pT2) had higher
expression levels of MMP-9 than superficial tumors (pTa) (p = 0.026). The same was noted for IL-8 that was more
expressed by invasive tumors (p = 0.015, p = 0.048). Most importantly tumor recurrence was related with higher
levels of both MMP-9 (p = 0.003) and IL-8 (p = 0.005).
Conclusion: We have demonstrated that the overexpression of MMP-9 and higher expression of IL-8 are related to
unfavorable prognostic factors of urothelial bladder cancer and tumor recurrence and may be useful in the follow up of
the patients.
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Background
Bladder cancer (BC) is the second most common malig-
nancy of the urinary tract. Approximately 383,300 new
cases are estimated for 2011 world-wide [1]. Ninety per-
cent of BC are urothelial carcinomas, previously named
transitional cell carcinomas, and the majority are papil-
lary low-grade, non-muscle invasive that recur in up to
80 % of cases but rarely progress to muscle invasion [2].
In contrast, 10 to 20 % of tumors are muscle invasive at
diagnosis, and 50 % of patients die from metastatic dis-
ease [3]. The molecular pathways of BC have been
investigated to identify new potential markers for diag-
nosis, disease monitoring, prognosis and development of
new targeted therapies [2,3].
Degradation of basal membranes and the extracellular
matrix (ECM) is essential for tumor invasion and develop-
ment of metastases, and matrix metalloproteinases
(MMPs) are potent proteolytic enzymes that are known to
play a key role in these processes. Within the MMP fam-
ily, Matrix Metalloproteinase 2 (MMP-2) (gelatinase A,
72 kDa) and Matrix Metalloproteinase 9 (MMP-9) (gelati-
nase B, 92 kDa) cleave type IV collagen and gelatin, which
are the main structural components of the basal mem-
brane [4]. At the post-translational level, all MMPs
are under control of specific tissue inhibitors (TIMPs).
TIMP-1 specifically inhibits MMP-9 and TIMP-2
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inhibits MMP-2, moreover, it has been reported that
Reversion-inducing cysteine-rich protein with Kazal
motifs (RECK) inhibits both MMP2 and MMP-9. Consid-
ering stimulation, membrane type-1 MMP (MT1-MMP),
also known as MMP14 is one of main activators, and also
Interleukin-8 (IL-8) upregulates MMP2 and MMP9 in
tumor cells, which is thought to be responsible for its
angiogenic activity. The balance between secreted MMPs
and their specific regulators plays an important role in
maintaining connective tissue homeostasis in normal
tissue [5].
In neoplastic diseases, an imbalance between MMPs
and their regulators, leading to an excess of degradative
activity, is assumed to be linked to the invasive character
of tumor cells [6,7]. Expression of MMP-9 and MMP-2
has been implicated in the development and progression
of many neoplasias, such as prostate [8], colorectal [9]
and lung cancer [10].
The aim of the present study was to investigate
whether MMP-9 e MMP-2 and its specific inhibitors,
TIMP-1 and TIMP-2, MMP-14, IL-8 and RECK, are
expressed in a reproducible, specific pattern in BC. Add-
itionally, we evaluated the correlation between the ex-
pression of these genes and three important prognostic
parameters, histological grade, pathological stage and
angiolymphatic invasion. Also we analyzed the profile of
MMPs and inhibitors with tumor recurrence.
Patients and Methods
Patients
The study was conducted using surgical specimens from
40 patients with BC who underwent transurethral resec-
tion in our institution between 2006 and 2008. The
demographic, clinical and pathological data are
described in Table 1. As control, we used normal bladder
tissue from five male patients who had undergone retro-
pubic prostatectomy to treat benign prostatic hyperpla-
sia; the mean age of the control group was 64.0 years
old, ranging from 60 to 70. These cases were randomly
selected from our database. All subjects provided
informed consent to participate in the study and to allow
their biological samples to be genetically analyzed. Ap-
proval for the study was given by the Institutional Board
of Ethics (no. 0105/09).
RNA Isolation and cDNA Synthesis
All tumor samples were obtained from surgical speci-
mens and immediately frozen at −170 °C in liquid nitro-
gen. A slide with a mirror of the frozen fragment was
stained with hematoxylin and eosin to verify that the
tumor represented at least 75 % of the fragment in
patients with cancer and to demonstrate the absence of
tumor in those without.
Total RNA was isolated with an RNAaqueous Kit
(Applied Biosystems, CA, USA) according to the manu-
facturer’s instructions. RNA concentration was deter-
mined by 260/280 nM absorbance using a Nanodrop ND-
1000 spectrophotometer (Thermo Scientific). cDNA was
generated using a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, CA, USA). The reac-
tions were incubated at 25 °C for 10 min, followed by 37 °
C for 120 min and 85 °C for 5 min. The cDNA was stored
at −20 °C until further use.
Quantitative Real-Time PCR and Gene Expression
Expression levels of the genes were analyzed by qRT-
PCR using an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems). Target sequences were amplified
in a 10-μl reaction containing 5 μl of TaqMan Universal
PCR Master Mix, 0.5 μl of TaqMan Gene Expression
Assays (primers and probes; see Table 2), 1 μl of cDNA
and 3.5 μl of DNase-free water. The PCR cycling condi-
tions were 2 minutes at 50 °C, 10 minutes at 95 °C, and
then 40 cycles of 15 seconds at 95 °C and 1 min at 60 °
C. A TaqMan B2M assay was utilized as the endogenous
control (Table 2).
We used the ΔΔCT method to calculate the relative
expression of the target genes using the formula ΔΔCT=
(CT target gene, BC sample - CT endogenous control,
BC sample) – (CT target gene, normal bladder tissue
sample - CT endogenous control, normal bladder tissue
Table 1 Demographic characteristics of 40 patients with
Bladder Cancer
Cases
Age (years)
Mean 69.0
Min - Max (47–87)
Gender
Man n (%) 31 (71.5)
Woman n (%) 9 (22.5)
Grade
Low n (%) 18 (45.0)
High n (%) 22 (55.0)
Stage
pTa n (%) 19 (47.5)
pT1 n (%) 13 (32.5)
pT2 n (%) 8 (20.0)
Angiolinfatic invasion
Without n (%) 36 (90.0)
With n (%) 4 (10.0)
Recurrence
Without n (%) 21 (67.7%)
With n (%) 10 (32.3%)
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sample sample). The fold change in gene expression was
calculated as 2-ΔΔCT.
Statistical analysis
Qualitative variables were expressed as numbers and
percentages. For analysis of expression according to
pathological stage, grade, angiolymphatic invasion
and recurrence, we used the T test for homogeneous
variables or Mann–Whitney test for heterogeneous
variables. Statistical analysis was performed using
SPSS 19.0 for Windows, and significance was set at
p ≤0.05.
Results
MMP-9 was overexpressed in 59.0 % of patients (Figure 1).
High-grade tumors exhibited significantly higher MMP-9
levels compared to low grade tumors (p=0.012). The same
was found for invasive tumors (pT1-pT2) that showed
higher expression levels than superficial tumors (p=0.026)
(Table 3). Regarding tumor recurrence, we observed that
patients with tumor recurrence showed higher expression of
MMP-9 and IL-8 when compared with patients that not re-
curred (p=0.003; p=0.005) (Table 4). We did not find dif-
ferences in gene expression related to angiolymphatic
invasion.
IL-8 was underexpressed in the majority of cases
(67.5 %) compared with normal controls (figure 1). We
also found correlation of IL-8 expression in relation to
tumor grade. High grade tumors showed significantly
higher levels of IL-8 (p = 0.003). The same was detected
for pT1 and pT2 invasive tumors that showed higher ex-
pression of IL-8 when compared to noninvasive tumors
pTa (p = 0.015, p = 0.048). Regarding tumor recurrence,
patients who have recurred showed higher expression of
IL-8 (p = 0.005). Again, there was no correlation between
IL-8 expression and angiolymphatic invasion (p = 0.161)
(Table 3).
Almost all patients showed underexpression of MMP-
2, TIMP-1, TIMP-2, MMP-14 and RECK (92,5 %,
72.5 %, 95.0 %, 72.5 % and 97.4 %) (Figure 1). We did
not find significant differences between the expression
of these genes with histological grade, pathological stage,
angiolymphatic invasion (Table 3), or tumor recurrence
(Table 4).
Discussion
The present study demonstrates that MMP-9 is overex-
pressed and TIMP-1 and RECK are underexpressed in
malignant bladder tissues compared with normal bladder
tissues. We demonstrated also that MMP-2 and its regu-
lators (TIMP-2, MMP-14 and IL-8) are underexpressed
in BC. Most importantly we found increased levels of
MMP-9 and IL-8 in high grade, invasive and recurrent
tumors.
Extensive studies have revealed that malignant inva-
sion and metastasis require ECM degradation, mainly by
MMPs [11]. Excessive or inappropriate expression of
MMPs may contribute to the pathogenesis of cancer in a
wide variety of cases by facilitating tissue degradation.
Currently, there are more than 20 identified MMPs that
can be categorized by substrate specificity. Despite the
clinical significance of the pathogenetic impact of MMPs
in human cancer, including BC, only a few studies of
MMPs are available in the literature, and those mainly
analyze protein expression [12].
In the present study, we have shown not only that
MMP-9 is overexpressed in cancer tissue, but also that
MMP-9 levels are significantly higher in patients with
high grade and infiltrative tumors, two very important
prognostics factors.
The same occurred considering IL-8 expression, be-
sides the fact that IL-8 is underexpressed in cancer tis-
sue, the relation between higher IL-8 expression and
unfavorable prognostic characteristics could be related
to the fact that IL-8 is important for tumor progression,
but not for tumor initiation or promotion.
MMP-9 and IL-8 expression levels increased together
with tumor invasiveness, suggesting that they are prob-
ably associated with a worse outcome in BC. This is the
Table 2 Primers utilized
Gene Assay
MMP2 Hs00234422_m1
MMP9 Hs00957562_m1
TIMP1 Hs00212624_m1
TIMP2 Hs00234278_m1
MMP14 Hs00237119_m1
RECK Hs01019179_m1
IL8 HS99999034_m1
B2M Hs99999907_m1
Figure 1 Expression levels of the three genes in BC tissue
compared with normal bladder tissue. Fold change in expression
was calculated using the 2-ΔΔCT method.
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first time that a study has shown a correlation between
high grade, invasive tumors and IL-8 mRNA expression
in BC. Increased MMP-9 expression has also been
shown to have an independent prognostic impact on op-
erable non-small cell lung cancer [13] and renal cell car-
cinoma [14], and increased IL-8 expression has been
associated with worse prognostic of colon cancer [15].
Another important finding of our study was the rela-
tionship between MMP-9 and IL-8 higher levels and
tumor recurrence during a long follow-up period (mean
of 40 months). The mean expression of MMP-9 and IL-
8 in patients with recurrence was greater than six times
that observed in patients without recurrence. This result
might reflect an important biological phenomenon that
could be confirmed in larger studies and that could be-
come a tool to identify patients likely to progress. MMPs
are abundantly expressed in malignant tumors regardless
of their origin, and a significant correlation between
increased MMP expression and a poor prognosis in
terms of survival has been demonstrated in several cases
[16,17]. As a result, the possibility of MMPs being used
as tumor markers has been suggested.
At the post-translational level, all MMPs are under the
control of specific tissue inhibitors (TIMPs) that bind
proximal to the catalytic domain of MMPs, preventing
substrate attachment. TIMPs are not simply regulators
of MMP activity; they also have multifunctional roles
that include cell growth promotion and inhibition of
angiogenesis [18]. Four TIMPs have been identified.
They inhibit all MMPs, forming non-covalent complexes
with the active forms. Among them, TIMP-1 selectively
binds pro-MMP-9 and is considered the main inhibitor
of MMP-9, TIMP-2 binds pro-MMP-2. The reversion-
inducing cysteine-rich protein with Kazal motifs (RECK)
gene was identified as an inducer of a flat morphology in
v-Ki ras–transformed NIH3T3 cells [19]. RECK expres-
sion is observed in normal human organs; however, sev-
eral oncogenic factors, such as activated Ras [20], EBV
latent membrane protein 1 [21], and HER-2/neu [22]
suppress the expression of RECK. Additionally, it has
been reported that RECK overexpression decreases the
amount of active MMP-2 and MMP-9 in conditioned
medium and inhibits metastatic activity in vitro [23] and
in vivo [24]. Considering activation of MMPs, MT1-
MMP is a key enzyme in tumor angiogenesis and metas-
tasis: it hydrolyzes a variety of ECM components, and is
a physiological activator of pro-MMP-2 and MMP-9. IL-
8 is involved in the transcription induction of MMP-2
increasing stromal invasion by tumor cells facilitating
angiogenesis and development of metastasis.
Interestingly, our results demonstrate that there is an
upregulation of MMP-9 and a downregulation of its spe-
cific inhibitors, TIMP-1 and RECK, in BC. Otherwise, we
demonstrated that the low expression of TIMP-2, MMP-
14 and IL-8 may be responsible for the decreased MMP-2
expression in BC tissue.
Conclusions
In conclusion, this is the first study to indicate the prog-
nostic relevance of MMP-9 and IL-8 mRNA expression in
BC, as demonstrated by the significant correlation be-
tween its expression and invasive, high grade tumors and
also BC recurrence. These findings suggest the possibility
of using the profiles of MMP-9 and IL-8 as prognostic
Table 3 Relative expression of the genes in the malignant bladder tissue according to grade, Pathological stage and
angiolinfatic invasion
Grade Median (min-max) Pathological Stage Median (min-max) Angiolinfatic Invasion Median (min-max)
Genes Low (n=18) High (n=22) p pTa (n=19) pT1 (n=13) pT2 (n=8) p Without (n=36) With (n=4) p
MMP2 0.125(0.50-2.10) 0.166(0.02-1.60) 0.904 0.165(0.05-2.10) 0.109(0.02-0.34) 0.226(0.05-1.60) 0.200 0.130 (0.02-2.10) 0.229 (0.13-0.67) 0.148
MMP9 0.680(0.05-38.9) 3.291(0.03-125.1) 0.012 0.687(0.00-38.9) 8.532 (0.00-125) 2.938(0.18-25.8) 0.048 1.250 (0.00-125) 2.938 (1.01-13.2) 0.333
TIMP1 0.489(0.10-4.02) 0.508(0.07-12.01) 1.000 0.398(0.10-4.02) 0.326 (0.07-4.13) 0.967(0.16-12.0) 0.169 0.443 (0.07-12.0) 0.978 (0.44-1.91) 0.148
TIMP2 0.076(0.01-8.42) 0.110(0.01-32.5) 0.427 0.077(0.01-8.42) 0.090(0.01-0.47) 0.255(0.01-32.5) 0.247 0.085 (0.01-32.5) 0.255 (0.09-0.84) 0.101
MMP14 0.469(0.02-2.87) 0.493(0.14-30.4) 0.798 0.516(0.29-2.87) 0.336 (0.14-1.67) 0.756(0.02-30.4) 0.08 0.464 (0.02-30.4) 0.540 (0.46-1.62) 0.557
RECK 0.175(0.00-1.65) 0.129(0.01-0.88) 0.606 0.224(0.00-1.65) 0.046 (0.01-0.88) 0.240(0.01-0.71) 0.953 0.224 (0.00-1.65) 0.09(0.03-0.35) 0.772
IL8 0.075(0.00-37.2) 0.783(0.01-13.63) 0.003 0.087(0.00-37.2) 0.750 (0.02-13.6) 2.042(0.01-12.9) 0.015 0.132 (0.00-37.2) 2.412 (0.30-5.85) 0.161
Fold change in gene expression was calculated using the ΔΔCT method (QRel = 2-ΔΔCT).
Table 4 Relative expression of the genes in the malignant
bladder tissue according to recurrence
Recurrence Median (min-max)
Genes without (n=21) with (n=10) p
MMP2 0.106 (0.04-1.23) 0.223(0.05-0.67) 0.529
MMP9 0.976 (0.03-25.9) 6.323(0.43-125.1) 0.003
TIMP1 0.397 (0.08-2.06) 0.692(0.16-4.13) 0.114
TIMP2 0.075 (0.01-32.5) 0.270(0.03-0.84) 0.456
MMP14 0.516(0.02-5.31) 0.419(0.28-1.62) 0.390
RECK 0.288(0.01-1.65) 0.090(0.01-0.81) 0.681
IL8 0.096(0.00-13.6) 0.783(0.11-37.2) 0.005
Fold change in gene expression was calculated using the ΔΔCT method (QRel
= 2-ΔΔCT).
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marker and, in the future, might inspire the development
of targeted drugs.
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